| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Alosetron D3 Hydrochloride targets the serotonin 5-HT3 receptor, a ligand-gated ion channel that is widely distributed in the central and peripheral nervous systems, including the enteric nervous system of the gastrointestinal tract. 5-HT3 receptors mediate the effects of serotonin on gastrointestinal motility, secretion, and visceral sensation. By antagonizing 5-HT3 receptors, Alosetron reduces gastrointestinal motility, decreases fluid secretion, and attenuates visceral pain, thereby alleviating symptoms of diarrhea-predominant IBS. The deuterated D3 form is used as an analytical internal standard for quantifying Alosetron in biological samples.
|
|---|---|
| ln Vitro |
In vitro, Alosetron (parent compound) acts as a potent and highly selective 5-HT3 receptor antagonist. The compound binds to 5-HT3 receptors with high affinity, competitively blocking serotonin binding and inhibiting receptor-mediated ion flux. In cellular assays using cells expressing 5-HT3 receptors, Alosetron inhibits serotonin-induced calcium influx and neuronal depolarization. The D3-labeled form is expected to exhibit identical in vitro receptor binding and activity to the parent compound, making it suitable as an internal standard for quantification. The compound's selectivity for 5-HT3 over other serotonin receptors contributes to its therapeutic profile.
|
| ln Vivo |
In vivo, Alosetron is clinically used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women. It was first approved by the FDA in 2000 but was later withdrawn due to safety concerns (ischemic colitis and severe constipation) and subsequently reapproved with restricted use. Alosetron reduces abdominal pain, diarrhea, and urgency in IBS patients. The deuterated D3 form is used as an internal standard for pharmacokinetic studies and therapeutic drug monitoring, enabling accurate quantification of Alosetron levels in plasma and urine samples by LC-MS/MS.
|
| Enzyme Assay |
In vitro receptor binding assays for Alosetron are performed using membrane preparations from cells expressing recombinant human 5-HT3 receptors. Radiolabeled ligands such as [3H]-GR65630 or [3H]-BRL43694 are used. Membranes are incubated with varying concentrations of Alosetron or the D3 internal standard in assay buffer at room temperature for 60-90 minutes. Bound and free radioligands are separated by rapid filtration through glass fiber filters. Filter-bound radioactivity is quantified by liquid scintillation counting. Ki values are calculated using the Cheng-Prusoff equation. Functional assays measure serotonin-induced calcium influx in cells expressing 5-HT3 receptors using fluorescent calcium indicators.
|
| Cell Assay |
Cellular assays for Alosetron are performed using cell lines expressing 5-HT3 receptors, such as HEK-293 cells transfected with 5-HT3A or 5-HT3AB receptors. Cells are cultured in appropriate medium and seeded in 96-well plates. Cells are loaded with fluorescent calcium indicator (e.g., Fluo-4) and treated with serial dilutions of Alosetron (0.001-10 microM) prior to stimulation with serotonin (10-100 microM). Calcium influx is measured using a fluorescence plate reader. IC₅0 values for inhibition of serotonin-induced calcium influx are calculated from dose-response curves. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
In vivo animal studies for Alosetron are conducted in rodent models of gastrointestinal motility and visceral hypersensitivity. Rats or mice are administered Alosetron orally or intraperitoneally at doses of 0.01-1 mg/kg. Gastrointestinal transit is measured by charcoal meal or Evans blue dye transit assays. Visceral pain is assessed by colorectal distension-induced abdominal withdrawal reflex. Fecal pellet output and water content are measured. Pharmacokinetic parameters are determined from plasma samples by LC-MS/MS using the D3 internal standard. Efficacy is compared to vehicle control and standard 5-HT3 antagonists.
|
| ADME/Pharmacokinetics |
Alosetron D3 Hydrochloride (CAS#: 1189919-71-8) has molecular formula C1₇H1₆D3ClN4O and molecular weight 333.83. The compound is a deuterium-labeled form of Alosetron hydrochloride, a potent and highly selective serotonin 5-HT3 receptor antagonist. Alosetron is used clinically for severe diarrhea-predominant IBS in women (brand name Lotronex). The D3-labeled analog is used as an internal standard for pharmacokinetic studies and therapeutic drug monitoring. Storage should be at -20degC, protected from light and moisture. For research use only.
|
| Additional Infomation |
Alosetron D3 Hydrochloride (CAS#: 1189919-71-8) is the deuterium-labeled form of Alosetron hydrochloride, a potent and highly selective serotonin 5-HT3 receptor antagonist. Alosetron (brand name Lotronex) is used clinically to manage severe diarrhea-predominant irritable bowel syndrome (IBS) in women. By blocking 5-HT3 receptors in the gastrointestinal tract, Alosetron reduces gastrointestinal motility, decreases fluid secretion, and attenuates visceral pain. The D3-labeled analog is used as an internal standard in LC-MS/MS bioanalytical methods for pharmacokinetic studies, therapeutic drug monitoring, and clinical research. For research use only, not for human therapeutic applications.
|
| Molecular Formula |
C17H15D3N4O.HCL
|
|---|---|
| Molecular Weight |
333.8304
|
| Exact Mass |
333.143
|
| CAS # |
1189919-71-8
|
| Related CAS # |
Alosetron Hydrochloride;122852-69-1;Alosetron (Hydrochloride(1:X));132414-02-9;Alosetron;122852-42-0;Alosetron-d3;1190043-13-0;Alosetron ((Z)-2-butenedioate);122852-43-1
|
| PubChem CID |
46780129
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.148
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
442
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N1C2=C(C3=CC=CC=C31)C(=O)N(CC2)CC4=C(NC=N4)C.Cl
|
| InChi Key |
FNYQZOVOVDSGJH-MUTAZJQDSA-N
|
| InChi Code |
InChI=1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H/i2D3;
|
| Chemical Name |
2-[(5-methyl-1H-imidazol-4-yl)methyl]-5-(trideuteriomethyl)-3,4-dihydropyrido[4,3-b]indol-1-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9955 mL | 14.9777 mL | 29.9554 mL | |
| 5 mM | 0.5991 mL | 2.9955 mL | 5.9911 mL | |
| 10 mM | 0.2996 mL | 1.4978 mL | 2.9955 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
